血流储备分数指导的PCI在稳定性冠心病中的三年随访结果与成本效益:FAME 2试验
FAME 2试验将888例稳定性冠心病且血流储备分数降低的患者随机分配至PCI+药物治疗组(n=447)或单纯药物治疗组(n=441),随访3年。结果显示PCI组主要不良心脏事件显著低于药物治疗组(10.1% vs 22.0%,P<0.001),主要由紧急血运重建减少驱动(4.3% vs 17.2%,P<0.001)。PCI组初始费用较高但3年总费用相似,增量成本效益比在3年时为每质量调整生命年1600美元。
要点
- FFR指导的PCI在稳定性冠心病患者中3年主要不良心脏事件显著低于单纯药物治疗。
- 获益主要来自紧急血运重建率降低,死亡和心肌梗死数值上无显著差异。
- PCI组3年总费用与药物治疗组相似,增量成本效益比具有经济吸引力。
核心结论
- 在血流储备分数降低的稳定性冠心病患者中,FFR指导的PCI相比单纯最佳药物治疗改善长期结局且具有经济吸引力。
研究设计与样本
- FAME 2试验为随机对照试验,共纳入888例稳定性单支或多支冠心病且血流储备分数降低的患者,随机分为PCI+药物治疗组(n=447)和单纯药物治疗组(n=441)。
主要发现
- 3年主要不良心脏事件PCI组为10.1%,药物治疗组为22.0%(P<0.001)。
- 3年紧急血运重建率PCI组为4.3%,药物治疗组为17.2%(P<0.001)。
- 死亡和心肌梗死PCI组为8.3%,药物治疗组为10.4%(P=0.28)。
- PCI组在3年随访所有时间点心绞痛严重程度均显著更轻。
关键数值与推荐
- 上述结果在敏感性分析中稳健。
临床怎么用
- 对于稳定性冠心病且FFR提示存在血流动力学意义狭窄的患者,FFR指导的PCI可减少紧急血运重建并改善心绞痛,且3年总费用与单纯药物治疗相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies found that percutaneous coronary intervention (PCI) does not improve outcome compared with medical therapy (MT) in patients with stable coronary artery disease, but PCI was guided by angiography alone. FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) compared PCI guided by fractional flow reserve with best MT in patients with stable coronary artery disease to assess clinical outcomes and cost-effectiveness. METHODS: A total of 888 patients with stable single-vessel or multivessel coronary artery disease with reduced fractional flow reserve were randomly assigned to PCI plus MT (n=447) or MT alone (n=441). Major adverse cardiac events included death, myocardial infarction, and urgent revascularization. Costs were calculated on the basis of resource use and Medicare reimbursement rates. Changes in quality-adjusted life-years were assessed with utilities determined by the European Quality of Life-5 Dimensions health survey at baseline and over follow-up. RESULTS: Major adverse cardiac events at 3 years were significantly lower in the PCI group compared with the MT group (10.1% versus 22.0%; P<0.001), primarily as a result of a lower rate of urgent revascularization (4.3% versus 17.2%; P<0.001). Death and myocardial infarction were numerically lower in the PCI group (8.3% versus 10.4%; P=0.28). Angina was significantly less severe in the PCI group at all follow-up points to 3 years. Mean initial costs were higher in the PCI group ($9944 versus $4440; P<0.001) but by 3 years were similar between the 2 groups ($16 792 versus $16 737; P=0.94). The incremental cost-effectiveness ratio for PCI compared with MT was $17 300 per quality-adjusted life-year at 2 years and $1600 per quality-adjusted life-year at 3 years. The above findings were robust in sensitivity analyses. CONCLUSIONS: PCI of lesions with reduced fractional flow reserve improves long-term outcome and is economically attractive compared with MT alone in patients with stable coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01132495.
引用
- Fearon WF, Nishi T, De Bruyne B, et al. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2017. PMID: 29097450. doi:10.1161/CIRCULATIONAHA.117.031907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。